Featured Bioprocessing Editorial

  1. Military Tool For Vulnerability Assessment: The CARVER + Shock Technique
    5/13/2019

    CARVER + Shock is a vulnerability assessment tool that can help manufacturers of medicinal products protect their products from deliberate contamination. Originally developed by the U.S. military, the technique can also be applied to raw/starting materials, production, distribution, and commercial and retail sales.

  2. Techniques For Risk-Based Validation Using ASTM E2500
    5/10/2019

    This article explores validation’s role in efficiency and cost management, in an approach to ASTM E2500 from a scientific, value-added perspective

  3. To Err Is Human: Contextual Communication’s Impact On Data Integrity
    5/8/2019

    Despite the best efforts of those responsible for data integrity, the potential for human error is directly and indirectly impacted by the corporate, the national/regional , and quality culture of an organization.

  4. How The Purple Book Continuity Act Could Challenge Biosimilars & The FDA
    5/7/2019

    On March 5, 2019, Representative Anna Eshoo (D-CA) introduced H.R. 1520, the “Purple Book Continuity Act of 2019.” The bill addresses the availability of information about approved biological products that may support the development of biosimilar products. It has five cosponsors in the House, drawn from both sides of the aisle, and was considered with five other bills by the House Energy and Commerce Committee on April 3, 2019. The Committee advanced the bill, along with five others, as a step toward addressing runaway drug pricing.

  5. Training Production Operators In Aseptic Technique: Common Pitfalls And How To Avoid Them
    5/2/2019

    Retraining an operator involved in a microbiological excursion is almost always part of the corrective and preventative action (CAPA), yet repeat excursions and deviations due to improper aseptic technique still routinely occur. So, why do some operators still have difficulty executing the task after completing such intensive training programs?

  6. Demonstrating Value And Securing Patient Access For Cell And Gene Therapies
    5/2/2019

    Because the parameters for ex vivo cell and gene therapy manufacturing differ considerably from chemical drug production, life sciences companies are likely to encounter challenges along key stages of the product life cycle.

  7. Incorporating Natural Hazards & Distributed Infrastructure Into Risk Management For Biopharma Operations
    4/25/2019

    Natural hazard events may seem like distant topics to some in the biopharmaceutical industry, but they hold relevance for all companies. Opportunities exist for risk management, including an important lesson in avoiding the gradual acceptance of such events as normal, until an even greater catastrophic event occurs.

  8. An Intro To Adverse Event Reporting And Product Complaints
    4/23/2019

    Managing complaints and controlling adverse events are critical tasks for a pharmaceutical company. While varying international regulations for adverse event reporting and product complaint handling make it difficult to automate processes and implement SOPs, it is necessary for companies to successfully resolve incidents and continue on a path to innovation.

  9. Analysis Of The Trastuzumab Biosimilar Market As Herceptin Exclusivity Nears An End
    4/23/2019

    Within the last few years, the FDA has taken steps to approve more biosimilar products and has committed to providing for a competitive landscape. The three latest biosimilars to be approved by the FDA have all been biosimilars to Herceptin. Further, Pfizer’s Trazimera, the most recently approved trastuzumab biosimilar, has sparked intrigue. As a result, Genentech is bracing for Herceptin biosimilar commercial launches in 2019.

  10. Risk Assessment Of Objectionable Microorganisms In Nonsterile Pharmaceuticals
    4/19/2019

    This is Part 2 of a two-part article on objectionable microorganisms in the nonsterile microbiology industry It discusses a risk-based approach to determine if a microorganism is objectionable for an application.